Active substance
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). Advate does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Iblias can be used for all age groups.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.